EGFR and non-small cell lung carcinoma: Although we expected a high frequency of detection of EGFR mutations in this study because of the high proportion of adenocarcinomas (92.3%), we detected EGFR mutations in only 28.2% of the patients enrolled, a lower frequency than in two previous reports on Japanese NSCLC patients (Takano et al, 2005; Asano et al, 2006).